Variant‐specific discrepancy when quantitatingBCR‐ABL1e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay-Reference-Cited by-同舟云学术

Variant‐specific discrepancy when quantitatingBCR‐ABL1e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay

Published:2019-05 Issue:1 Volume:103 Page:26-34
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Kjaer Lasse¹^ORCID,Skov Vibe¹,Andersen Morten T.²,Aggerholm Anni³,Clair Philippe⁴,Gniot Michal⁵,Soeby Karen⁶,Udby Lene¹,Dorff Mikkel H.¹,Hasselbalch Hans¹,Pallisgaard Niels⁷

Affiliation:

1. Department of Hematology Zealand University Hospital Roskilde Denmark

2. Department of Clinical Genetics Rigshospitalet Copenhagen Denmark

3. Hemodiagnostic Laboratory Aarhus University Hospital Aarhus Denmark

4. Plateforme PCR Université de Montpellier Montpellier France

5. Department of Hematology and Stem Cell Transplantation Poznan University of Medical Sciences Poznan Poland

6. Department of Clinical Biochemistry Zealand University Hospital Roskilde Denmark

7. Department of Surgical Pathology Zealand University Hospital Roskilde Denmark

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13238

Reference24 articles.

1. The molecular biology of chronic myeloid leukemia;Deininger MW;Blood,2000

2. Molecular biology of bcr-abl1–positive chronic myeloid leukemia

3. Does the breakpoint within the major breakpoint cluster region (M‐bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature;Mills KI;Blood,1991

4. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival

5. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-20

2. Variant‐specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia;International Journal of Laboratory Hematology;2024-06-05

3. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis;American Journal of Hematology;2024-05-20

4. High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation;Cells;2024-04-22

5. Failure of Treatment-Free Remission after a Prolonged Deep Molecular Response in Patients with Chronic Myeloid Leukemia;Acta Haematologica;2024-04-04